Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zur neuralen Herztherapie bei Herzinsuffizienz (NECTAR-HF) (NECTAR-HF)

26. Oktober 2026 aktualisiert von: Boston Scientific Corporation

Neurale Herztherapie für Herzinsuffizienz-Studie

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Studienübersicht

Detaillierte Beschreibung

The objectives of this study are to assess the impact of right vagal nerve stimulation on left ventricular remodeling, functional capacity, quality of life, and other measures in heart failure patients over a 6-month period. In addition, the study will assess the safety of the NECTAR-HF study system over an 18-month period.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

118

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Brussels, Belgien, 1200
        • UCL Bruxelles
      • Göttingen, Deutschland, 37075
        • Universitätsmedizin Göttingen
      • Hamburg, Deutschland, 20246
        • Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf
      • Leipzig, Deutschland, 04103
        • Universitätsklinikum Leipzig
    • Brandenburg
      • Bernau bei Berlin, Brandenburg, Deutschland, 16321
        • Immanuel Klinikum Bernau Herzzentrum Brandenburg
      • Lille, Frankreich, 59037
        • CHRU de Lille - Hôpital Cardiologique
    • Nancy
      • Vandœuvre-lès-Nancy, Nancy, Frankreich, 54500
        • Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy
      • Milan, Italien, 20162
        • Azienda Ospedaliera Niguarda Cà Granda
      • Naples, Italien, 80131
        • A. O. Dei Colli - Monaldi
      • Pavia, Italien, 27100
        • Policlinico San Matteo
      • Eindhoven, Niederlande, 5623EJ
        • Catharina Ziekenhuis Eindhoven
      • Utrecht, Niederlande, 3584CX
        • UMC Utrecht
      • Barcelona, Spanien, 08036
        • Hospital Clinic de Barcelona
      • Madrid, Spanien, 28041
        • Hospital Doce de Octubre
    • Navarre
      • Pamplona, Navarre, Spanien, 31008
        • Clínica Universitaria de Navarra, Avenida Pio XII s/n
      • Prague, Tschechien, 15030
        • Nemocnice Na Homolce
      • London, Vereinigtes Königreich, SE5 9RS
        • King's College Hospital NHS Foundation Trust
    • England
      • Bristol, England, Vereinigtes Königreich, BS2 8HW
        • University Hospitals Bristol, NHS Foundation Trust
      • Liverpool, England, Vereinigtes Königreich, L14 3PD
        • Liverpool Heart and Chest Hospital, NHS Foundation Trust
      • London, England, Vereinigtes Königreich, W1G 8PH
        • The Heart Hospital, University College London Hospitals, NHS Foundation Trust
      • London, England, Vereinigtes Königreich, W2 1NY
        • Imperial College Healthcare NHS Trust, St. Mary's Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age 18 or above, and of legal age to give informed consent specific to national laws
  • Willing and capable of providing informed consent
  • Capable of participating in all testing associated with this clinical investigation
  • Stable symptomatic heart failure NYHA class II-III
  • Left ventricular (LV) ejection fraction equal or smaller than 35 %
  • Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater
  • Prescribed to optimal pharmacologic therapy

Exclusion Criteria:

  • QRS larger than 130 ms
  • Patients who have been hospitalized for heart failure and who required the use of HF IV therapy within 30 days before enrollment
  • Patients unable to tolerate anesthesia required for implant
  • Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 90 days before enrollment
  • Patients whose primary cause of heart failure is mitral or aortic valve disease, with a severe classification
  • Patients with persistent or permanent atrial fibrillation within 90 days prior to enrollment
  • Pacemaker indicated patients
  • Patients whose heart failure is due to congenital heart disease
  • Patients who have started treatment for sleep apnea or sleep disordered breathing with therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen supplementation within the previous 6 months prior to enrollment
  • Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
  • Patients with documented chronic obstructive lung disease
  • Patients on or indicated for renal dialysis
  • Type 1 diabetic patients
  • Type 2 diabetic patients that have been treated with insulin for more than 5 years prior to enrollment
  • Patients with a life expectancy of less than 12 months per physician judgment
  • Patients involved in any concurrent clinical investigation
  • Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
  • Patients with a prior cardiac transplant or expecting a heart transplant operation within the next 12 months
  • Patients with a prior vagotomy
  • Patients with prior or existing vagal nerve stimulation treatment
  • Patients implanted with any active implantable medical device other than a left sided single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar sensing, or a left sided CRT device with each sensing channel programmed to either bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year prior to enrollment. The total number of CRT patients will not exceed 30
  • Patients with locally implanted semi-/permanent devices such as vascular catheters, etc. that would interfere with the NECTAR-HF study system
  • Patients with previously implanted devices on the right side that became infected before removal
  • Patients with previous neck surgery and resultant scar formation that interferes with the ability to implant the study system on the right side of the neck (Thyroid/parathyroid, carotid artery etc)
  • Patients with known recurrent nerve paralysis
  • Patients who have undergone radiotherapy for thyroid disease/cancer
  • Patients who have existing or prior tracheotomy
  • Patients with severe vertebral cervical disease and limited mobility in the neck; includes those that frequently wear a brace
  • Patients with carotid murmur/vascular bruit/carotid artery lesion
  • Patients with known/suspected vascular malformation in carotid/vertebral circulatory bed
  • Patients who are likely to need an MRI of the neck area because of previous medical conditions

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Therapy

Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.

The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.

Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Schein-Komparator: Control

Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Left Ventricular End-systolic Dimension (LVESD)
Zeitfenster: LVESD at Baseline and at 6-months post Baseline

Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.

The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.

The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).

LVESD at Baseline and at 6-months post Baseline
Percentage of Surviving Participants
Zeitfenster: 18-months

As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.

18-months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
LVEF, Left Ventricular Ejection Fraction
Zeitfenster: LVEF at Baseline and at 6-months after Baseline

LVEF, left ventricular ejection fraction.

LVEF at Baseline and at 6-months after Baseline
Exercise Capacity, Peak VO2
Zeitfenster: Measurements at Baseline and at 6-months after Baseline

Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.

Measurements at Baseline and at 6-months after Baseline
LVESV, Left Ventricular End Systolic Volume
Zeitfenster: At Baseline and at 6-months after Baseline

Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm

At Baseline and at 6-months after Baseline

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Faiez Zannad, M.D., Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

21. September 2011

Primärer Abschluss (Tatsächlich)

1. Mai 2014

Studienabschluss (Geschätzt)

30. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

28. Juni 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

28. Juni 2011

Zuerst gepostet (Geschätzt)

30. Juni 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

28. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

26. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren